Phathom maintains 2026 net revenue forecast of $310 million-$325 million
PHAT•Phathom Pharmaceuticals maintained its 2026 net revenue guidance of $310 million to $325 million. Third-quarter 2026 net revenue was $84.7 million, up approximately 71% from a year earlier.
1. Guidance maintained
Phathom Pharmaceuticals kept its 2026 net revenue guidance at $310 million to $325 million. Operating expense guidance remains $235 million to $245 million, excluding stock-based compensation, while gross-to-net discounts are forecast at 55% to 59%.
2. Profitability outlook
The company expects operating profitability for the remainder of 2026 and the full year, excluding stock-based compensation, and expects cash flow to turn positive in 2027. Third-quarter 2026 net revenue reached $84.7 million, up approximately 71% from a year earlier.
